Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.25
Bid: 27.00
Ask: 27.50
Change: -0.35 (-1.27%)
Spread: 0.50 (1.852%)
Open: 27.60
High: 27.60
Low: 27.25
Prev. Close: 27.60
HVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - hVIVO plc

27 Dec 2019 08:07

RNS Number : 1037Y
Numis Securities Limited
27 December 2019
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Numis Securities Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

hVIVO plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Nominated Adviser to hVIVO plc

(d) Date dealing undertaken:

24/12/2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

None

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary 5p

Sale

1,000

12.00 GBX

12.00 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

27/12/2019

Contact name:

Jamie Goldstein

Telephone number:

0207 260 1600

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEREAPAXAEDNFEF
Date   Source Headline
15th Apr 20247:00 amRNSAnnual Report & Notice of AGM
9th Apr 20247:09 amRNSFinal results
27th Mar 20247:00 amRNSNotice of Results
22nd Mar 20243:03 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSLong Term Incentive Plan / PDMR Notification
14th Feb 20241:14 pmRNSResult of Secondary Placing
14th Feb 20247:00 amRNSProposed Secondary Placing of Ordinary Shares
2nd Feb 202412:44 pmRNSHolding(s) in Company
30th Jan 20247:00 amRNSTrading update
8th Jan 20247:00 amRNSBroker change
2nd Jan 20247:00 amRNS£6.3m HRV contract signed with biotech client
13th Dec 20237:00 amRNS£16.8m RSV contract & Trading ahead of guidance
5th Oct 20237:00 amRNSPositive results from flu human challenge study
12th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSExercise of Warrants
29th Aug 20237:00 amRNSPlans for a new larger state-of-the-art facility
24th Aug 20237:00 amRNSNotice of Results
26th Jul 20237:00 amRNSTrading update
25th Jul 20237:00 amRNSFlu B challenge model
28th Jun 20237:00 amRNShMPV human challenge model
14th Jun 20238:00 amRNSDirector dealings
23rd May 202312:36 pmRNSResult of AGM
28th Apr 20237:00 amRNSAnnual Report and Notice of AGM
26th Apr 20237:00 amRNSFDA Breakthrough and Fast Track for US biotech
25th Apr 20237:00 amRNSFinal results
19th Apr 20237:10 amRNSNotice of Results
6th Apr 20233:54 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSPositive results from flu human challenge study
29th Mar 20237:00 amRNSPresentation at World Vaccine Congress
23rd Mar 20237:00 amRNSExercise of Options
16th Mar 20237:00 amRNSOmicron human challenge model update
6th Feb 20239:05 amRNSSecond Price Monitoring Extn
6th Feb 20239:00 amRNSPrice Monitoring Extension
6th Feb 20237:05 amRNSLong Term Incentive Plan / PDMR Notification
6th Feb 20237:00 amRNS£6.8m RSV human challenge contract signed
25th Jan 20239:06 amRNSSecond Price Monitoring Extn
25th Jan 20239:00 amRNSPrice Monitoring Extension
25th Jan 20237:00 amRNSTrading update
17th Jan 20237:00 amRNSEUR3.2m Venn contract with global pharma client
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn
4th Jan 20234:35 pmRNSPrice Monitoring Extension
4th Jan 20237:00 amRNS£5.2m RSV contract and Notice of Trading update
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
3rd Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 202311:05 amRNSSecond Price Monitoring Extn
3rd Jan 202311:00 amRNSPrice Monitoring Extension
19th Dec 20227:00 amRNSImutex Phase I data published

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.